Drug Shortage Report for HALOPERIDOL INJECTION, USP

Last updated on 2021-08-19 History
Report ID 133505
Drug Identification Number 02406411
Brand name HALOPERIDOL INJECTION, USP
Common or Proper name Haloperidol Injection, USP 5 mg/mL 1 mL
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HALOPERIDOL
Strength(s) 5MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 mL
ATC code N05AD
ATC description ANTIPSYCHOTICS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2021-06-01
Actual start date 2021-06-01
Estimated end date 2021-08-20
Actual end date 2019-08-20
Shortage status Avoided shortage
Updated date 2021-08-19
Company comments [5/27/2021] Fresenius Kabi Canada Ltd. regrets to advise that due to a delay in production we will be encountering a supply interruption on our Haloperidol Injection, USP 5 mg/mL MD Vial 1 mL, effective June 1st, 2021 until August 23rd, 2021.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2021-08-19 French Compare
v8 2021-08-19 English Compare
v7 2021-06-02 French Compare
v6 2021-05-27 French Compare
v5 2021-05-27 English Compare
v4 2021-05-27 French Compare
v3 2021-05-27 English Compare
v2 2021-02-05 French Compare
v1 2021-02-05 English Compare

Showing 1 to 9 of 9